While waiting to price its initial public offering, Anacor Pharmaceuticals Inc. signed a deal with GlaxoSmithKline plc for the discovery, development and commercialization of small-molecule, boron-based antivirals and antibacterials. (BioWorld Today)

MAP Pharmaceuticals Inc. is adding $60 million through an initial public offering to support an upcoming Phase III trial of its late-stage aerosolized products for asthma and migraine. (BioWorld Today)